Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jeffrey D Neidhart"'
Autor:
Jonathan Afari, Tanya M. Spektor, Carley Turner, Alexa Cohen, Alberto Bessudo, Haresh Jhangiani, Nashat Gabrail, Samir Kubba, Jeffrey D. Neidhart, Shahrooz Eshaghian, Regina A. Swift, Benjamin M. Eades, Clara Kim, Susanna Kim, Robert Vescio, James R. Berenson
Publikováno v:
Experimental Hematology. 114:54-60
Autor:
Lavannya Pandit, Julia Garcia-Diaz, Gerard J. Criner, Benjamin Kramer, Jamie Freedman, Maria F. González-Lara, Rachel Baden, Linda Yau, Jian Han, Shalini V. Mohan, Miriam L Cameron, Reena Shah, Carlos Salama, Victoria Chávez, Martha Mekebeb-Reuter, Ferdinando Lima de Menezes, Jeffrey D. Neidhart, Emma Kaplan-Lewis, W. Reiss, Beverly Assman
Publikováno v:
New England Journal of Medicine
The New England Journal of Medicine
The New England Journal of Medicine
Background Coronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. Despite the disproportionate incidence of Covid-19 among underserved and racial and ethnic minority populations, the safety and efficacy of the anti
Autor:
Ferdinando Lima de Menezes, W. Reiss, Emma Kaplan-Lewis, Maria F. González-Lara, Beverly Assman, Miriam L. Cameron, Linda Yau, Reena Shah, Gerard J. Criner, Jian Han, Julia Garcia-Diaz, Jamie Freedman, Martha Mekebeb-Reuter, Benjamin Kramer, Rachel Baden, Shalini V. Mohan, Victoria Chávez, Jeffrey D. Neidhart, Lavannya M. Pandit, Carlos Salama
BackgroundCoronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. Safety and efficacy of the anti–interleukin-6 receptor antibody tocilizumab was evaluated in patients hospitalized with Covid-19 pneumonia.MethodsNo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4ade2fe46511f13e8cfbe55a0f84968
https://doi.org/10.1101/2020.10.21.20210203
https://doi.org/10.1101/2020.10.21.20210203
Autor:
Wolfgang Hiddemann, Robert Marcus, Martin J. S. Dyer, Guillaume Cartron, Georg Hess, Ram Malladi, Michael Herold, Andrea Knapp, Michael Kneba, David Cunningham, Chiara Rusconi, Christian Buske, John G. Gribben, Takayuki Ishikawa, Harald Zeuner, Jeffrey D Neidhart, William Townsend, Ulrich Keller, Jun Zhu, Olivier Catalani
Publikováno v:
Blood. 132:1597-1597
Introduction: Immunochemotherapy is standard of care treatment for previously untreated patients (pts) with advanced stage follicular lymphoma (FL). However, the majority of pts relapse, with around 20% relapsing within 2 years. Obinutuzumab (GA101;
Autor:
Warren Chow, Glen J. Weiss, Mark E. Davis, Jeffrey Longmate, John L. Ryan, Yun Yen, D. Lynn Kalinoski, James A. Neidhart, Edward G. Garmey, Marianna Koczywas, Robert J. Morgan, Jeffrey D. Neidhart, Thomas Schluep, Chung Hang Jonathan Choi, Jamie Oliver, Joseph Chao, Joanna J. Peterkin, Jungyeon Hwang, Timothy W. Synold, Stephen J. Forman, Ramesh K. Ramanathan, Roger J. Melton, Przemyslaw Twardowski, Dawn Bassett, Vincent Chung
Publikováno v:
Investigational New Drugs. 31:986-1000
Patients with advanced solid malignancies were enrolled to an open-label, single-arm, dose-escalation study, in which CRLX101 was administered intravenously over 60 min among two dosing schedules, initially weekly at 6, 12, and 18 mg/m(2) and later b
Autor:
Roy Mackintosh, Nashat Y. Gabrail, Haresh S. Jhangiani, Robert Vescio, Alberto Bessudo, Ashkan Lashkari, James R. Berenson, Tanya M. Spektor, Michael Oren Robinson, Tina Maluso, Regina A. Swift, Samir V. Kubba, Jeffrey D. Neidhart, Alexa Cohen, Ibrahim Nakhoul
Publikováno v:
Journal of Clinical Oncology. 36:e20012-e20012
e20012Background: Pomalidomide (POM) is a third–generation immunomodulatory drug shown to be safe and effective for the treatment of relapsed/refractory multiple myeloma (RRMM) patients (pts) previ...
Autor:
Vamsidhar Velcheti, Niklas J. Mackler, Shaker R. Dakhil, David S. Shames, Brian Hunis, Tarek Mekhail, Fadi Hayek, Jeffrey D. Neidhart, Cindy Yun, Sarah M. Paul, Sylvia Hu, Nadeem Ikhlaque, Michaela L. Tsai, Christian Antoine El Khoury, Edward S. Kim, See-Chun Phan, Fabio Volterra, Mark A. Socinski, Joan H. Schiller
Publikováno v:
Journal of Clinical Oncology. 35:TPS9103-TPS9103
TPS9103 Background: The anti–PD-L1 monoclonal antibody atezolizumab inhibits the interaction of PD-L1 with its receptors PD-1 and B7.1, thereby restoring T-cell immunity. In the Phase III OAK study, patients with previously treated advanced NSCLC h
Autor:
Michael Oren Robinson, Tina Maluso, Nashat Y. Gabrail, Ashkan Lashkari, Alexa Cohen, Roy Mackintosh, Ibrahim Nakhoul, Samir V. Kubba, Jeffrey D. Neidhart, James R. Berenson, Shahrooz Eshaghian, Alberto Bessudo, Robert Vescio, Tanya M. Spektor, Regina A. Swift, Haresh S. Jhangiani
Publikováno v:
Journal of Clinical Oncology. 35:e19528-e19528
e19528 Background: Pomalidomide (POM) is a third –generation immunomodulatory drug shown to be safe and effective for the treatment of relapsed/refractory multiple myeloma (RRMM) for patients (pts) previously treated with bortezomib and lenalidomid
Autor:
Lori A. Coerver, Marianna Koczywas, Ramesh K. Ramanathan, Glen J. Weiss, Edward G. Garmey, Yun Yen, D. Lynn Kalinoski, John J. Ryan, James A. Neidhart, Jeffrey D. Neidhart, Joanna J. Peterkin
Publikováno v:
Molecular Cancer Therapeutics. 10:A97-A97
Introduction: Topoisomerase-1-inhibiting camptothecin (CPT) and derivatives such as irinotecan (CPT-11) and topotecan demonstrate clinical utility across multiple cancer types. Use of these agents remains limited by insufficient tumor exposure and hi
Autor:
Jeffrey D. Neidhart, Edward B. Garon, Nashat Y. Gabrail, S. P. Lu, J. A. Neidhart, Moacyr Ribeiro de Oliveira, J. Balkissoon, Fairooz F. Kabbinavar
Publikováno v:
Journal of Clinical Oncology. 29:7559-7559
7559 Background: Inhibition of angiogenesis has clinical benefits in NSCLC. Depriving tumors of blood flow by adding bevacizumab (B) to other vasculature-directed agents has been hampered by toxici...